119136 | Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem

119136
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Pricing & Availability

      Catalogue NumberAvailability Packaging Qty/Pack Price Quantity
      US1119136-10MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      In Stock 
      Discontinued
      Limited Quantities Available
      Availability to be confirmed
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 10 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
          Catalogue Number119136
          Brand Family Calbiochem®
          Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
          References
          ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
          Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
          Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
          Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
          Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
          Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
          Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
          Product Information
          CAS number37739-05-2
          FormWhite solid
          Hill FormulaC₁₅H₂₀ClN₅O₄
          Chemical formulaC₁₅H₂₀ClN₅O₄
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetA1
          Primary Target K<sub>i</sub>2.3 nM
          Purity≥99% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          References

          Reference overview
          Burgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
          Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
          Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
          Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
          Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
          Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
          Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision28-March-2013 JSW
          Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
          DescriptionAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
          FormWhite solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number37739-05-2
          Chemical formulaC₁₅H₂₀ClN₅O₄
          Structure formulaStructure formula
          Purity≥99% by HPLC
          SolubilityDMSO (100 mM) or H₂O (5 mM)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
          Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
          Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
          Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
          Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
          Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
          Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.